- Home
- CAI vs ALKS Comparison
CAI vs ALKS Comparison
Compare CAI & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAI | ALKS |
|---|---|---|
| Founded | 2008 | 1987 |
| Country | United States | Ireland |
| Employees | 1846 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.1B |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | CAI | ALKS |
|---|---|---|
| Price | $15.40 | $37.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 14 |
| Target Price | $30.91 | ★ $43.43 |
| AVG Volume (30 Days) | ★ 3.0M | 1.9M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,475,899,000.00 |
| Revenue This Year | $25.24 | $24.26 |
| Revenue Next Year | $22.32 | $4.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.19 | $25.17 |
| 52 Week High | $42.50 | $39.56 |
Technical Indicators
Market Signals| Indicator | CAI | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 40.41 | 63.95 |
| Support Level | $14.19 | $27.65 |
| Resistance Level | $19.79 | $39.56 |
| Average True Range (ATR) | 1.03 | 1.16 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 22.17 | 65.34 |
Price Performance
Historical ComparisonAbout CAI Caris Life Sciences Inc.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.